Written questions by Perteghella.

What assessment he has made of the consistency of (a) response times and (b) service provision by Patient Advice and Liaison Services (PALS) across NHS organisations.

No assessment has been made of the consistency of National Health Service trusts in responding to Patient Advice and Liaison Service (PALS) enquiries.Generally, there are no required national timeframes or service standards for responding to enquires made to PALS. However, where PALS are responding to complaints raised under the formal NHS complaints process, they must follow the requirements in The Local Authority Social Services and National Health Service Complaints (England) Regulations 2009 which set out in law the minimum standards NHS organisations must adhere to.The 10-Year Health Plan committed the Department and NHS England to improving the handling of patient complaints, including to update complaint regulations. It is intended that this will also consider related matters, such as the introduction of new forms of feedback and the role of PALS services. This will be within the portfolio of the new National Director for Patient Experience, for which recruitment is underway.

Whether his Department plans to issue national guidance on (a) response times and (b) service standards for Patient Advice and Liaison Services (PALS).

No assessment has been made of the consistency of National Health Service trusts in responding to Patient Advice and Liaison Service (PALS) enquiries.Generally, there are no required national timeframes or service standards for responding to enquires made to PALS. However, where PALS are responding to complaints raised under the formal NHS complaints process, they must follow the requirements in The Local Authority Social Services and National Health Service Complaints (England) Regulations 2009 which set out in law the minimum standards NHS organisations must adhere to.The 10-Year Health Plan committed the Department and NHS England to improving the handling of patient complaints, including to update complaint regulations. It is intended that this will also consider related matters, such as the introduction of new forms of feedback and the role of PALS services. This will be within the portfolio of the new National Director for Patient Experience, for which recruitment is underway.

Whether the Modern Service Framework for Palliative and End of Life Care will be supported by a) national accountability mechanisms and (b) sustainable funding to ensure equitable access to high-quality palliative care services.

The Modern Service Framework (MSF) for Palliative Care and End-of-Life Care will provide a clinically led, evidence-based framework to support sustained improvement in patient and carer outcomes, including reducing both inequality and unwarranted variation. Areas of action will be identified for those commissioning and delivering services with associated performance and outcome metrics to support system accountability. The MSF will seek to embed palliative care and end-of-life care within a strategic commissioning model that is centred on population need.NHS England is working closely with integrated care boards (ICBs) to support more strategic, data‑driven commissioning of palliative care and end-of-life care services. We are asking ICBs to have clear and transparent contractual arrangements in place for commissioned activity across all providers of palliative care, including hospices, to meet population health needs.

If he will use the Autumn Budget 2026 to provide long‑term, recurring revenue funding for hospices.

As with all fiscal matters, we cannot pre‑empt the Autumn Budget. Decisions on future funding will be taken through the usual Budget process and will be taken in the context of the wider public finances. The Government recognises the vital role that hospices play in supporting people at the end of life and their families.Palliative care services are included in the list of services an integrated care board (ICB) must commission, including hospice services. This promotes a more consistent national approach and supports commissioners in prioritising palliative care and end-of-life care. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.In addition, the Government has provided significant financial support for the hospice sector, including £125 million of capital funding to improve adult and children and young people’s hospice facilities and £80 million of revenue funding for children and young people’s hospices for three years, from 2026/27 to 2028/29.The Government is developing a Modern Service Framework (MSF) for Palliative Care and End-of-Life Care for England, with a planned publication date of Autumn 2026. Through our MSF, we will closely monitor the shift towards the strategic commissioning of palliative care and end-of-life care services to ensure that services reduce variation in access and quality. We will also consider contracting and commissioning arrangements as part of our MSF.

What estimate his Department has made of the cost of missed appointments in (i) Warwickshire and (ii) nationally; and what steps he is taking to reduce the number of missed appointments.

The Department has made no formal estimate of the cost of missed appointments in Warwickshire or nationally.However, we’re clear that reducing missed appointments is an important part of improving elective care and making best use of National Health Service capacity to cut waiting times. The Government has committed, in the Elective Reform Plan, to focussed action to reduce missed appointments, including enhancing two-way communication between hospitals and patients, and to use artificial intelligence to predict who will miss appointments, to save up to one million missed appointments. NHS England continues to support the validation of waiting lists, as part of the Government's plans for a more productive and improved approach to elective care which is better for patients. Effective validation helps trusts to understand the true size of their waiting list for better planning and can help avoid missed appointments to reduce overall waiting times.Locally, trusts are also using data‑led approaches to prioritise proactive appointment reminders, making greater use of the NHS App and patient portals, and targeting specialties with higher non‑attendance rates through outpatient improvement work.

What guidance is issued to GPs on recognising symptoms of neuroendocrine cancers.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What assessment he has made of the adequacy of patient access to specialist treatments for neuroendocrine cancer, including peptide receptor radionuclide therapy.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

Whether neuroendocrine cancers are included in NHS England’s wider early cancer diagnosis initiatives, including the Faster Diagnosis Standard.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What steps he is taking to improve the early diagnosis of neuroendocrine cancers.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What steps he is taking to ensure timely patient access to innovative treatments for rare cancers, including neuroendocrine cancers.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What steps he is taking to ensure neuroendocrine cancer patients receive appropriate psychological, nutritional, and long‑term follow‑up support.

Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.

What assessment his Department has made of the number of emergency hospital admissions for respiratory conditions in (a) South Warwickshire, (b) the West Midlands region, and (c) England.

NHS England routinely collects data on emergency admissions, including the chief complaint recorded at attendance.In February 2026, there were 273,367 emergency admitted attendances in England, 14.9% of which recorded airway or breathing-related conditions as the chief complaint.In the West Midlands, there were 57,805 emergency admitted attendances, with 15.8% relating to airway or breathing‑related conditions.At the South Warwickshire NHS Foundation Trust, there were 2,025 emergency admitted attendances, 12.8% of which were for airway or breathing‑related conditions as the chief complaint.

What consideration his Department has given to the potential role of a respiratory Modern Service Framework in reducing winter pressures on the NHS by improving outcomes for long-term respiratory conditions and short-term respiratory illnesses such as flu.

Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia.The Government will consider other long-term conditions for future waves of modern service frameworks, including respiratory conditions. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity. There has not, therefore, been a specific assessment made in relation to winter pressures.NHS England, working with the Department, the UK Health Security Agency, and other partners, took action to reduce the impact of respiratory conditions on the National Health Service during the winter of 2025/26. Further details of the actions taken to reduce demand on acute services during winter is available at the following link:https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/

Whether his Department plans to introduce a national standard for providing (a) full and (b) timely responses to complaints made within healthcare settings across England.

The Local Authority Social Services and National Health Service Complaints (England) Regulations 2009 set out in law the minimum standards National Health Service organisations must adhere to in respect of their complaint handling arrangements. This includes the need to investigate complaints speedily and efficiently and keep the complainant informed during the investigation. The response must include, amongst other things, an explanation of how the complaint has been considered and the conclusions reached.We have committed in the 10-Year Health Plan to reform the NHS complaints process and set clear standards for both the timeliness and the quality of responses to complaints. We expect this to be within the portfolio of the new National Director for Patient Experience, for which recruitment will soon be underway.

What consideration he has given to amending the NHS Charges to Overseas Visitors Regulations 2015 to remove the exclusion of assisted conception services for Ukrainian nationals who are lawfully resident in the UK under (a) the Homes for Ukraine and (b) Ukraine Permission to Extend visa schemes.

Assisted conception services often require long-term treatment, lasting months or years, which does not align with the short-term nature of all visas that are covered by the Immigration Health Surcharge, including the Homes for Ukraine and Ukraine Permission Extension Schemes. There are currently no plans to amend the NHS (Charges to Overseas Visitors) Regulations 2015.

For what reason assisted conception services are excluded from the exemption from NHS charges for people in the UK under (a) the Homes for Ukraine and (b) Ukraine Permission to Extend visa schemes.

Assisted conception services often require long-term treatment, lasting months or years, which does not align with the short-term nature of all visas that are covered by the Immigration Health Surcharge, including the Homes for Ukraine and Ukraine Permission Extension Schemes. There are currently no plans to amend the NHS (Charges to Overseas Visitors) Regulations 2015.

What steps he is taking to help tackle the harm caused by sodium valproate to people in (a) England, (b) Warwickshire, and (c) Stratford-on-Avon.

Everyone who has been harmed from sodium valproate has our deepest sympathies.The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care.In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the NHS in Newcastle and Manchester. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, better coordination of care, and reduced reliance on emergency care. Findings from the pilot will inform future decisions on the commissioning of services, subject to funding.The Government is also carefully considering the Patient Safety Commissioner’s recommendations made in the Hughes Report, which includes proposed approaches to redress for those harmed by sodium valproate. I recently met the Patient Safety Commissioner to provide an update on the ongoing health initiatives led by the Department regarding sodium valproate and pelvic mesh, and agreed to providing an update on her report recommendations in due course.

How many specialist Parkinson’s nurses are currently employed within the NHS in (a) England and (b) Coventry and Warwickshire.

The Department does not hold a central count of the number of specialist Parkinson’s nurses employed across the National Health Service, either in England as a whole or in Coventry and Warwickshire specifically.Specialist Parkinson’s nurses play a vital role in supporting people with Parkinson’s disease through personalised care, medicines management, and advice on self‑management. However, these posts are not recorded as a discrete workforce category in national workforce datasets. Workforce planning, including decisions about the number and type of specialist nurses needed locally, is the responsibility of individual employers and their integrated care boards (ICBs), which are best placed to assess the needs of their populations.The Department does not hold data on the number of neurologists with specialist training in Parkinson’s disease, either nationally in England or within Coventry and Warwickshire. National workforce datasets do not record condition‑specific sub‑specialisms within neurology, and responsibility for determining local specialist workforce configurations rests with individual employers and ICBs.As of October 2025, there are 51 full-time equivalent (FTE) doctors working in the specialty of neurology within the Coventry and Warwickshire ICB area. This is a decrease of one, or 2.2%, compared to last year and an increase of 23, or 79.3%, compared to five years ago. This includes 21 FTE consultants. This is an increase of two, or 9.9%, compared to last year and six, or 41.5%, compared to five years ago.

How many neurologists working in the NHS have specialist training in Parkinson’s disease in (a) England and (b) Coventry and Warwickshire.

The Department does not hold a central count of the number of specialist Parkinson’s nurses employed across the National Health Service, either in England as a whole or in Coventry and Warwickshire specifically.Specialist Parkinson’s nurses play a vital role in supporting people with Parkinson’s disease through personalised care, medicines management, and advice on self‑management. However, these posts are not recorded as a discrete workforce category in national workforce datasets. Workforce planning, including decisions about the number and type of specialist nurses needed locally, is the responsibility of individual employers and their integrated care boards (ICBs), which are best placed to assess the needs of their populations.The Department does not hold data on the number of neurologists with specialist training in Parkinson’s disease, either nationally in England or within Coventry and Warwickshire. National workforce datasets do not record condition‑specific sub‑specialisms within neurology, and responsibility for determining local specialist workforce configurations rests with individual employers and ICBs.As of October 2025, there are 51 full-time equivalent (FTE) doctors working in the specialty of neurology within the Coventry and Warwickshire ICB area. This is a decrease of one, or 2.2%, compared to last year and an increase of 23, or 79.3%, compared to five years ago. This includes 21 FTE consultants. This is an increase of two, or 9.9%, compared to last year and six, or 41.5%, compared to five years ago.

What assessment his Department has made of how NHS services support people with coeliac disease who are facing financial difficulties.

We recognise the pressures people are facing with the rising cost of living and the increased costs incurred by people with coeliac disease because they have to buy gluten-free options, which are often more expensive than their non-gluten-free equivalents.The Department carried out an analysis of this issue as part of its Equalities Impact Assessment which was published as part of the consultation on the Availability of gluten-free foods on prescription in primary care. A copy of the assessment following this consultation is available at the following link:https://www.gov.uk/government/consultations/availability-of-gluten-free-foods-on-nhs-prescriptionWe looked at the equality impact assessment and the consultation responses and, as a result, made the decision to retain gluten-free bread and mixes on National Health Service prescription. This will help enable people with coeliac disease to obtain their basic food needs and mitigate the risk that those on lower incomes are not able to purchase their own gluten-free foods from retail outlets.The national prescribing position in England remains that gluten-free bread and mixes can be provided to all eligible coeliac patients on an NHS prescription, and a wide range of these items continue to be listed in Part XV of the Drug Tariff. This means that prescribers can issue NHS prescriptions, based on a shared decision between prescriber and patient, while also being mindful of local and national guidance.